Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.
Juan-Giner A, Tchaton M, Jemmy JP, Soumah A, Boum Y, Faga EM, Cisse M, Grais RF.
Juan-Giner A, et al.
Vaccine. 2019 Nov 15;37(48):7171-7177. doi: 10.1016/j.vaccine.2018.09.009. Epub 2018 Sep 25.
Vaccine. 2019.
PMID: 30266489
Free article.
Clinical Trial.
The most frequently reported symptoms were headache, fatigue, arthralgia, subjective fever and myalgia. Among participants that completed fever diaries (n = 887), post-vaccination fever was reported by 15.22%. Comparing to the unvaccinated group, local reaction, fat …
The most frequently reported symptoms were headache, fatigue, arthralgia, subjective fever and myalgia. Among participants tha …